Travere Therapeutics Hits New 1-Year High After Analyst Upgrade

Biotech firm's stock surges on positive regulatory news and bullish analyst coverage

Apr. 14, 2026 at 2:09pm

Got story updates? Submit your updates here. ›

An extreme close-up of a series of gears, levers, and metallic components that make up the inner workings of a banking or financial institution, conveying a sense of the intricate machinery and institutional power behind the approval and commercialization of new pharmaceutical products.Travere Therapeutics' recent FDA approval for its rare disease drug highlights the complex financial infrastructure and institutional backing required to bring innovative medicines to market.San Diego Today

Shares of Travere Therapeutics (NASDAQ:TVTX) reached a new 52-week high after Wedbush Securities upgraded the stock and raised its price target. The biopharmaceutical company recently received full FDA approval for its lead drug FILSPARI, the first-ever treatment for the rare kidney disorder focal segmental glomerulosclerosis (FSGS).

Why it matters

The FDA approval of FILSPARI opens up a significant commercial opportunity for Travere, as FSGS is a rare disease with limited treatment options. The positive analyst coverage and bullish options activity suggest growing investor optimism around the company's growth prospects.

The details

Wedbush raised its price target on Travere Therapeutics from $39 to $44 and maintained an 'Outperform' rating on the stock. The upgrade comes after the FDA granted full approval for FILSPARI (sparsentan) to treat FSGS, a leading cause of end-stage kidney disease. FILSPARI is the first approved medicine for FSGS, which affects around 40,000 patients in the U.S. The company is now focused on commercializing the drug and expanding its patient reach.

  • On April 14, 2026, Travere Therapeutics' stock price reached a new 52-week high of $42.50.
  • On April 6, 2026, director Roy D. Baynes sold 10,000 shares of the company's stock.

The players

Travere Therapeutics, Inc.

A biopharmaceutical company headquartered in San Diego, California, dedicated to developing and commercializing therapies for rare kidney and genetic disorders.

Wedbush Securities

An investment firm that covers Travere Therapeutics and recently upgraded the stock to 'Outperform' while raising its price target.

Roy D. Baynes

A director at Travere Therapeutics who sold 10,000 shares of the company's stock on April 6, 2026.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

What’s next

The company is now focused on commercializing FILSPARI and expanding its patient reach for the treatment of FSGS, a rare kidney disorder.

The takeaway

Travere Therapeutics' recent FDA approval for its lead drug FILSPARI, combined with positive analyst coverage and bullish options activity, suggests the company is well-positioned to capitalize on the commercial opportunity in the rare disease space.